Showing 9001-9010 of 10271 results for "".
- DBV Technologies Presents Breakthrough Data at EAACI-WAO Congresshttps://practicaldermatology.com/news/20130702-dbv_technologies_presents_breakthrough_data_at_eaaci-wao_congress/2459506/DBV Technologies presented six clinical and preclinical presentations on Epicutaneaous Immunotherapy (EPIT) at the European Academy of Allergy & Clinical Immunology & World Allergy Organization & World Allergy & Asthma Congress (EAACI-WAO) in Milan, Italy. DBV's Viaskin technology was highlighted in
- MiraConnect Lets Candidates Interact with miraDry Treatment Veteranshttps://practicaldermatology.com/news/20130625-miraconnect_lets_candidates_interact_with_miradry_treatment_veterans/2459509/Offering an opportunity for interested to learn more about microwave-based therapy for hyperhidrosis, the miraConnect program from Miramar Labs enables treatment candidates to speak one-on-one with patients who have undergone the procedu
- Viscot Releases Prep-Resistant Ink Markerhttps://practicaldermatology.com/news/20130611-viscot_releases_prep-resistant_ink_marker/2459516/AllSkin Plus+ with Prep Resistant Ink is the first prep-resistant ink marker that offers maximum visibility and prep resistance on all skin tones. Its VIXL brilliant blue ink provides enhanced visibility even after prep and other fluids and remains visible up to 10 times longer than traditional ink.
- Renaissance and GlaxoSmithKline Transfer Nine Productshttps://practicaldermatology.com/news/20130605-renaissance_and_glaxosmithkline_transfer_nine_products/2459522/Renaissance Acquisition Holdings, LLC and GlaxoSmithKline entered into an agreement giving Renaissance the rights in the USA to manufacture, market, and sell six dermatology and three anti-viral products from GSK. The products from GSK and Stiefel, which will be marketed through Renaissance's bran
- Levia Targeted Phototherapy Now Part of Daavlinhttps://practicaldermatology.com/news/20130531-levia_targeted_phototherapy_now_part_of_daavlin/2459525/Daavlin has been appointed by Lerner Medical Devices to exclusively manufacture, sell, and support their Levia Targeted Home Phototherapy Device. The Levia device complements Daavlin's line of home units for the treatment of skin disorders such as psoriasis, vitiligo, and eczema. Product warranties
- New Technical Manager at Jurliquehttps://practicaldermatology.com/news/20130531-new_technical_manager_at_jurlique/2459527/Jurlique appointed Connie Lim to Technical Manager of Global Product Development. In her new role, Ms. Lim will drive innovative formula development, provide technical support, and monitor performance and key milestones in global new product development efforts. Ms. Lim comes to Jurlique with mor
- Valeant Pharmaceuticals to Acquire Bausch + Lombhttps://practicaldermatology.com/news/20130528-valeant_pharmaceuticals_to_acquire_bausch__lomb/2459529/
- Clark Pharmaceuticals, Ferndale Healthcare Launch DerMendhttps://practicaldermatology.com/news/20130521-clark_pharmaceuticals_ferndale_healthcare_launch_dermend/2459534/Clark Pharmaceuticals partnered with Ferndale Healthcare to launch DerMend Moisturizing Bruise Formula. The formula is predicated on the idea that skin over 50 tends to get thinner and bruises more easily. Blood thinners, even those like low-dose baby aspirin, can cause skin to bruise. DerMend is de
- JUVÉDERM VOLUMA™ XC Receives Unanimous Recommendation from FDA Panelhttps://practicaldermatology.com/news/20130514-juvderm_voluma_xc_receives_unanimous_recommendation_from_fda/2459545/The US Food and Drug Administration General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee voted unanimously that the benefits of JUVÉDERM VOLUMA™ XC, an injectable hyaluronic acid dermal filler for cheek augme
- Corena Therapeutics New to Industryhttps://practicaldermatology.com/news/20130513-corena_therapeutics_new_to_industry/2459546/The emerging Swiss dermatological products company Corena Therapeutics provides safe alternatives to popular treatments. Coresatin, its latest brand of five steroid-free creams, is safely formulated for pediatric patients, according to the